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ABSTRACT
This study tested the hypothesis that xenogeneic human umbilical cord-derived 
mesenchymal stem cell (HUCDMSC) therapy would improve survival rates in rats with 
acute respiratory distress-syndrome (ARDS, induction by 48 h inhalation of 100% 
oxygen) and sepsis-syndrome (SS, induction by cecal-ligation and puncture) (ARDS-
SS). Adult-male Sprague-Dawley rats were categorized into group 1 (sham-controls), 
group 2 (ARDS-SS), group 3 [ARDS-SS+HUCDMSC (1.2 x106 cells administered 1 h 
after SS-induction)], and group 4 [ARDS-SS+HUCDMSC (1.2 x106 cells administered 
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24 h after SS-induction)]. The mortality rate was higher in groups 2 and 4 than in 
groups 1 and 3 (all p<0.0001). The blood pressure after 28 h was lower in groups 2, 
3 and 4 (p<0.0001) than in group 1. Albumin levels and percentages of inflammatory 
cells in broncho-alveolar lavage fluid, and the percentages of inflammatory and 
immune cells in circulation, were lowest in group 1, highest in group 2, and higher in 
group 3 than group 4 (all p<0.0001). The percentages of inflammatory cells in ascites 
and kidney parenchyma showed identical patterns, as did kidney injury scores (all 
p<0.0001). EarlyHUCDMSC therapy reduced rodent mortality after induced ARDS-SS.
INTRODUCTION
Acute respiratory distress syndrome (ARDS) and 
sepsis syndrome with multiple organ failure (SS) are 
two global, growing diseases that have high in-hospital 
mortality [1–5]. The in-hospital mortality rate has been 
estimated to be from 26% to 63% for ARDS patients [6–
8], and 60% to 80% for SS patients [9–12].
The innate and adaptive immune responses 
defend the body from non-infectious, harmful 
substances and invasive microorganisms. Patients 
with both ARDS and SS (ARDS-SS) experience 
an uncontrolled immune response, inflammation, 
over-production of reactive oxygen species (ROS), 
over-activation (i.e., cascade) of complement, and 
endotoxin release from infectious microorganisms 
[4, 10, 13–24]. These complex hyper-inflammatory 
and immune responses are triggered in an attempt to 
eliminate the causative factors, but they also cause 
multi-organ damage in the host [17, 20], which could 
contribute to the high mortality in ARDS-SS [13–24]. 
Strategies that target these increased inflammatory and 
immune responses may have therapeutic potential.
Mesenchymal stem cell (MSC) therapy has the 
capacity to attenuate inflammation [16, 25–28] and 
down-regulate innate and adaptive immunity [16, 26–30] 
through suppressing immunogenicity [16, 26–31]. MSC 
therapy might improve the clinical outcomes in ARDS-
SS patients. However, prior to apply MSC therapy for 
human being, a preclinical study had to be first performed 
by using human being derived MSC (i.e., xenogeneic 
MSC) to prove not only the safety and efficacy but also 
the immune privilege of the MSC regardless for what kind 
of biological species. Accordingly, this preclinical study 
tested the hypothesis that xenogeneic human umbilical 
cord-derived mesenchymal stem cell (HUCDMSC) 
therapy could safely and effectively protect rodents from 
ARDS-SS, and improve prognostic outcome.
RESULTS
The albumin and inflammatory cytokine levels 
of bronchoalveolar lavage (BAL) fluid by day 5 
after ARDS-SS induction
BAL albumin level was lowest in group 1 (SC) 
and highest in group 2 (ARDS-SS). Group 3 (ARDS-SS 
+ HUCDMSC1h) showed a higher BAL albumin level 
than in group 4 (ARDS-SS + HUCDMSC24h) (Figure 1). 
Flow cytometry showed the same pattern between the 
four groups for three inflammatory biomarkers: CD11b/c, 
macrophage migration inhibitor factor (MIF), and Ly6G.
Figure 1: Albumin and proinflammatory cytokine levels in BAL fluid. (A) The albumin level in bronchoalveolar lavage (BAL) 
fluid, * vs. other groups with different symbols (†, ‡, §), p<0.001. (B) Flow cytometric analysis of CD11b/c+ cells in BAL fluid, * vs. 
other groups with different symbols (†, ‡, §), p<0.0001. (C) Flow cytometric analysis of Ly6G+ cells in BAL fluid, * vs. other groups 
with different symbols (†, ‡, §), p<0.0001. (D) Flow cytometric analysis of macrophage migratory inhibitor factor (MIF)-1+ cells in BAL 
fluid, * vs. other groups with different symbols (†, ‡, §), p<0.0001. Statistical analyses were performed by one-way ANOVA, followed by 
Bonferroni multiple comparison post hoc test (n=6 for each group). Symbols (*, †, ‡, §) indicate significance at the 0.05 level. SC = sham 
control; ARDS = acute respiratory distress syndrome; SS = sepsis syndrome; HUCDMSC = human umbilical cord-derived mesenchymal 
stem cell; 1h indicated HUCDMSC administration at 1 hour after SS induction; 24h indicated HUCDMSC administration at 24 hour after SS 
induction.
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Blood pressure and mortality by day 5 after 
ARDS-SS induction
By 28 h after sepsis induction, the systolic blood 
pressure was higher in group 1 than groups 2, 3, and 4, 
with no difference among groups 2, 3, and 4 (Figure 2). 
The mortality rate was higher in groups 2 and 4 (50%, 
40%, respectively) than in groups 1 and 3 (0%, 5%, 
respectively), P <0.0001 for 4 groups by log rank test. 
Additionally, pairwise comparisons (without Bonferroni’s 
correction) showed that: (1) Group 1 vs. 2, p = 0.0002; 
(2) Group 1 vs. 3, p = 0.317; (3) Group 1 vs. 4, p = 
0.002; (4) Group 2 vs. 3, P = 0.002; (5) Group 2 vs. 4, 
p = 0.306; (6) Group 3 vs. 4: p = 0.009 (Figure 2). We 
noted that the majority of animals in group 4 (ARDS-
SS + HUCDMSC24h) died after the HUCDMSCs were 
administered. This suggests only prompt HUCDMSC 
treatment lowered mortality after ARDS-SS induction.
Kidney injury and WT-1 expression by day 5 
after ARDS-SS induction
Kidney assessment was necessary because it is the 
major vulnerable abdominal visceral organ to be involved 
in cecal ligation and puncture (CLP)-induced SS. Light 
microscopy of hematoxylin and eosin (H & E)-stained 
kidney sections showed that average kidney injury 
score was highest in group 2, lowest in group 1, and 
higher in group 3 than in group 4. Immunohistochemical 
(IHC) staining demonstrated an identical pattern in the 
expression of Wilm’s tumor suppressor gene (WT-1), 
predominantly in podocytes (Figure 3).
Inflammatory cells in parenchyma of the kidney 
by IF by day 5 after ARDS-SS induction
Immunofluorescent (IF) microscopy found that the 
percentages of cellular expression of three inflammatory 
biomarkers (CD68, CD14 and MIF) were highest in 
group 2, lowest in group 1, and higher in group 3 than in 
group 4 (Figure 4).
Kidney injury biomarker and podocyte levels by 
day 5 after ARDS-SS induction
IF microscopy showed that the cellular expression 
of kidney injury molecule (KIM)-1, a kidney injury 
biomarker predominant in renal tubules, was increased 
the most in group 2. KIM-1 was higher in groups 3 and 
4 than in group 1, and higher in group 3 than group 4. 
IHC microscopy showed that the cellular expression of 
podocin, one component of the podocyte foot process, 
did not match the KIM-1 pattern between the four groups 
(Figure 5).
Figure 2: Systolic blood pressure (SBP) at 28 h after sepsis induction and mortality rate by day 5 after ARDS-SS 
induction. (A) SBP was measured from rat tail at 28 h after sepsis syndrome induction, * vs. †, p<0.001. (B) The result of Pair comparisons 
(i.e., expressed as bar charts) showed that the 5-day survival rate was higher in sham control and ARDS-SS + HUCDMSC1h than in ARDS-
SS + HUCDMSC24h. † vs. ‡, p<0.0003. (C) Kaplan Meier curve showed 5-day cumulative survival rate among the four groups. * vs. other 
groups with different symbols (†, ‡), p<0.0001 (for 4 groups by log rank test). Symbols (*, †, ‡) indicate significance at the 0.05 level. 
SC = sham control; ARDS = acute respiratory distress syndrome; SS = sepsis syndrome; HUCDMSC = human umbilical cord-derived 
mesenchymal stem cell; 1h indicated HUCDMSC administration at 1 hour after SS induction; 24h indicated HUCDMSC administration at 
24 hour after SS induction.
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Figure 3: Histopathological findings of rat kidney injury and cellular expression of WT-1 by day 5 after ARDS-SS 
induction. (A to D) Light microscopic findings of H & E stain (400x), demonstrating higher degree of loss of brush border in renal tubules 
(yellow arrows), tubular necrosis (green arrows), tubular dilation (red asterisk), protein cast formation (black asterisk), and dilation of 
Bowman’s capsule (blue arrows) in ARDS-SS group than in other groups. (E) * vs. other groups with different symbols (†, ‡, §), p<0.0001. 
(F to I) Illustrating the microscopic finding (400x) of immunohistochemical staining for identification of Wilm's tumor suppressor gene 1 
(WT-1), expressed predominantly in podocytes (gray color). (J) Analytical results of WT-1 expression, * vs. other groups with different 
symbols (†, ‡, §), p<0.0001. Scale bars: 20 µm. All statistical analyses were performed by one-way ANOVA, followed by Bonferroni 
multiple comparison post hoc test (n=8 for each group). Symbols (*, †, ‡, §) indicate significance at 0.05 level. SC = sham control; ARDS 
= acute respiratory distress syndrome; SS = sepsis syndrome; HUCDMSC = human umbilical cord-derived mesenchymal stem cell; 1h 
indicated HUCDMSC administration at 1 hour after SS induction; 24h indicated HUCDMSC administration at 24 hour after SS induction.
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Figure 4: Inflammatory cell infiltration in kidney parenchyma by day 5 after ARDS-SS induction. (A to D) 
Immunofluorescent (IF) microscopic finding (400x) for identification of CD68+ cells (green color). Nuclei were stained by DAPI 
(blue color). Red color in (C) and (D) indicated HUCDMSCs were found in kidney parenchyma. (E) Analytical result of number of 
CD68+ cells among the four groups, * vs. other groups with different symbols (†, ‡, §), p<0.0001. (F to I) IF microscopy (400x) 
for identification of CD14+ cells (green color). Nuclei were stained by DAPI (blue color). Red color in (H) and (I) indicated 
HUCDMSCs were found in kidney parenchyma. (J) Analytical result of number of CD14+ cells among the four groups, * vs. 
other groups with different symbols (†, ‡, §), p<0.0001. (K to M) Immunofluorescent (IF) microscopy (400x) for identification of 
macrophage migratory inhibitor factor (MIF)+ cells (green color). Nuclei were stained by DAPI (blue color). Red color in (L) and 
(M) indicated HUCDMSCs were found in kidney parenchyma. (N) Analytical result of number of MIF+ cell among the four groups, 
* vs. other groups with different symbols (†, ‡, §), p<0.0001. Scale bars: 20 µm. All statistical analyses were performed by one-way 
ANOVA, followed by Bonferroni multiple comparison post hoc test (n=8 for each group). Symbols (*, †, ‡, §) indicate significance 
(at 0.05 level). SC = sham control; ARDS = acute respiratory distress syndrome; SS = sepsis syndrome; HUCDMSC = human 
umbilical cord-derived mesenchymal stem cell; 1h indicated HUCDMSC administration at 1 hour after SS induction; 24h indicated 
HUCDMSC administration at 24 hour after SS induction.
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Figure 5: Microscopy of kidney injury biomarker and podocyte component in kidney parenchyma by day 5 after ARDS-
SS induction. (A to D) Immunofluorescent (IF) staining (400x) of kidney injury molecule (KIM)-1+ cells (green color). Nuclei were 
stained by DAPI (blue color). Red color in (C) and (D) indicated HUCDMSCs were found in kidney parenchyma. (E) Analytical result of 
number of KIM-1+ cells among the four groups * vs. other groups with different symbols (†, ‡, §), p<0.0001. (F to I) Immunohistochemical 
(IHC) microscopy (400x) for identification of cellular expression of podocin (gray color). (J) Analytical result of number of KIM-1+ 
cells among the four groups * vs. other groups with different symbols (†, ‡, §), p<0.0001. Scale bars: 20 µm. All statistical analyses were 
performed by one-way ANOVA, followed by Bonferroni multiple comparison post hoc test (n=8 for each group). Symbols (*, †, ‡, §) 
indicate significance at 0.05 level. SC = sham control; ARDS = acute respiratory distress syndrome; SS = sepsis syndrome; HUCDMSC = 
human umbilical cord-derived mesenchymal stem cell; 1h indicated HUCDMSC administration at 1 hour after SS induction; 24h indicated 
HUCDMSC administration at 24 hour after SS induction.
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Protein expression of inflammation biomarkers 
in parenchyma of the kidney by day 5 after 
ARDS-SS induction
The protein levels of nine indicators of 
inflammation [tumor necrosis factor (TNF)-α, interleukin 
(IL)-6, IL-1ß, MIF, nuclear factor (NF)-κB, matrix 
metalloproteinase (MMP)-9, inducible nitric oxide 
synthase (iNOS), tall-like receptor (TLR)-2 and TLR-4] 
were highest in group 2. The protein levels were also 
higher in group 3 than in groups 1 and 4, and higher in 
group 4 than in group 1 (Figure 6).
Protein expression of oxidative stress and 
apoptotic biomarkers in parenchyma of the 
kidney by day 5 after ARDS-SS induction
The protein levels of three indicators of oxidative 
stress (NOX-1, NOX-2, and oxidized protein) were 
highest in group 2, lowest in group 1, and higher in 
group 3 than in group 4. The same pattern between the 
four groups was observed in the protein expression 
of two indicators of apoptosis [cleaved caspase 3 
and cleaved poly (ADP-ribose) polymerase (PARP)] 
(Figure 7).
Figure 6: Protein expression of inflammatory biomarkers in kidney parenchyma by day 5 after ARDS-SS induction. (A) 
Illustration of grouping of the protein expressions (Part I) with same actin as internal control. (B) Protein expression of tumor necrosis factor 
(TNF)-α, * vs. other groups with different symbols (†, ‡, §), p<0.0001. (C) Protein expression of interleukin (IL)-6, * vs. other groups with 
different symbols (†, ‡, §), p<0.0001. (D) Protein expression of IL-1ß, * vs. other groups with different symbols (†, ‡, §), p<0.001. (E) Protein 
expression of tall-like receptor (TLR)-2, * vs. other groups with different symbols (†, ‡, §), p<0.0001. (F) Protein expression of TLR-4, * vs. 
other groups with different symbols (†, ‡, §), p<0.0001. (G) Illustrating grouping of the protein expressions (Part II) with same actin as internal 
control. (H) Protein expression of macrophage migratory inhibitor factor (MIF), * vs. other groups with different symbols (†, ‡, §), p<0.001. 
(I) Protein expression of nuclear factor (NF)-κB, * vs. other groups with different symbols (†, ‡, §), p<0.0001. (J) Protein expression of matrix 
metalloproteinase (MMP)-9, * vs. other groups with different symbols (†, ‡, §), p<0.001. (K) Protein expression of inducible nitric oxide synthase 
(iNOS), * vs. other groups with different symbols (†, ‡, §), p<0.001. All statistical analyses were performed by one-way ANOVA, followed by 
Bonferroni multiple comparison post hoc test (n=8 for each group). Symbols (*, †, ‡, §) indicate significance at 0.05 level. SC = sham control; 
ARDS = acute respiratory distress syndrome; SS = sepsis syndrome; HUCDMSC = human umbilical cord-derived mesenchymal stem cell; 1h 
indicated HUCDMSC administration at 1 hour after SS induction; 24h indicated HUCDMSC administration at 24 hour after SS induction.
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Inflammation biomarkers in ascites and 
circulation by flow cytometry by day 5 after 
ARDS-SS induction
In ascites, flow cytometry demonstrated that the 
percentages of cells testing positive for six inflammation 
biomarkers (CD11b/c, MIF, Ly6G, CD14, CD68/CD80, 
and CD68/CD163) were highest in group 2, lowest in 
group 1, and higher in group 3 than in group 4 (Figure 
8). In the circulation, an identical pattern was observed 
of three indicators of inflammation response (CD11b/c, 
Ly6G, and VCAM-1) (Figure 9). Circulating levels of 
Figure 7: Protein expression of oxidative stress and apoptotic biomarkers in kidney parenchyma by day 5 after ARDS-SS 
induction. (A) Illustration of grouping of the protein expressions (Part I) with same actin as internal control. (B) Protein expression of NOX-
1, * vs. other groups with different symbols (†, ‡, §), p<0.001. (C) Protein expression of NOX-2, * vs. other groups with different symbols 
(†, ‡, §), p<0.0001. (D) Protein expression of cleaved caspase 3 (c-Casp3), * vs. other groups with different symbols (†, ‡, §), p<0.001. (E) 
Protein expression of cleaved poly (ADP-ribose) polymerase (c-PARP), * vs. other groups with different symbols (†, ‡, §), p<0.0001. (F) 
Oxidized protein expression, * vs. other groups with different symbols (†, ‡, §), p<0.001. (Note: left and right lanes shown on the upper panel 
represent protein molecular weight marker and control oxidized molecular protein standard, respectively). M.W = molecular weight; DNP 
= 1-3 dinitrophenylhydrazone. All statistical analyses were performed by one-way ANOVA, followed by Bonferroni multiple comparison 
post hoc test (n=8 for each group). Symbols (*, †, ‡, §) indicate significance at 0.05 level. SC = sham control; ARDS = acute respiratory 
distress syndrome; SS = sepsis syndrome; HUCDMSC = human umbilical cord-derived mesenchymal stem cell; 1h indicated HUCDMSC 
administration at 1 hour after SS induction; 24h indicated HUCDMSC administration at 24 hour after SS induction.
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three indicators of immune cells (CD3/CD4, CD3/CD8, 
and Treg cells) also showed the same pattern among the 
four groups (Figure 9).
Immunofluorescence of inflammatory cells in 
ascites by day 5 after ARDS-SS induction
IF microscopy showed that the percentage of cells 
positive for two inflammation biomarkers in ascites (CD11 
and MIF) were highest in group 2, lowest in group 1, and 
higher in group 3 than in group 4 (Figure 10). The same 
pattern between the four groups was observed for IL-1ß, 
TLR-4, and CD11 (Figure 11).
DISCUSSION
This study investigated the impact of HUCDMSC 
therapy on the prognostic outcome in rats after inducing 
ARDS-SS. Early HUCDMSC treatment (i.e., 1 h after 
ARDS-SS induction) reduced rat mortality rate, but late 
HUCDMSC treatment (i.e., 24 h after ARDS-SS induction) 
did not improve the survival rate. ARDS-SS induction was 
always followed by an elevated inflammatory reaction, 
while HUCDMSC treatment suppressed it.
MSC therapy has reduced rodent mortality in SS 
[32], and both autologous and allogenic ADMSC have 
the capacity of immune privilege [16, 29, 31–33]. The 
present study showed that in animals with ARDS-SS, early 
administration of xenogeneic MSC reduces the mortality 
rate compared to no treatment. Exogenic MSC effectively 
saved ARDS-SS animals, which suggests that MSC may 
have universal immune privilege. Despite the success 
of the early treatment, late administration of xenogeneic 
MSC was not effective for rodents with ARDS-SS.
MSC treatment can attenuate the elevated 
inflammatory and immune reactions that frequently 
occur in acute tissue/organ injury and SS [16-18, 25-28, 
31-35]. Here, inflammatory biomarkers in circulation 
and body fluids (i.e., BAL and ascites) were higher in 
ARDS-SS animals than SC animals. Circulating immune 
cells displayed the same trend. All of these inflammatory 
immunogenetic biomarkers were suppressed in ARDS-SS 
Figure 8: Flow cytometry analysis of inflammatory biomarkers in ascites by day 5 after ARDS-SS induction. (A) Flow 
cytometry analysis of CD11b/c+ cells in ascites, * vs. other groups with different symbols (†, ‡, §), p<0.001. (B) Flow cytometry analysis of 
Ly6G+ cells in ascites, * vs. other groups with different symbols (†, ‡, §), p<0.0001. (C) Flow cytometry analysis of CD14+ cells in ascites, 
* vs. other groups with different symbols (†, ‡, §), p<0.0001. (D) Flow cytometry analysis of macrophage migratory inhibitor (MIF)+ cells 
in ascites, * vs. other groups with different symbols (†, ‡, §), p<0.0001. (E) Flow cytometry analysis of CD68/CD80+ cells in ascites, * 
vs. other groups with different symbols (†, ‡, §), p<0.0001. (F) Flow cytometry analysis of number of CD68/CD163+ cells in ascites, * vs. 
other groups with different symbols (†, ‡, §), p<0.001. All statistical analyses were performed by one-way ANOVA, followed by Bonferroni 
multiple comparison post hoc test (n=8 for each group). Symbols (*, †, ‡, §) indicate significance at 0.05 leve). SC = sham control; ARDS 
= acute respiratory distress syndrome; SS = sepsis syndrome; HUCDMSC = human umbilical cord-derived mesenchymal stem cell; 1h 
indicated HUCDMSC administration at 1 hour after SS induction; 24h indicated HUCDMSC administration at 24 hour after SS induction.
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Figure 9: Flow cytometry analysis of inflammatory and immune cells in circulation by day 5 after ARDS-SS induction. 
(A) Flow cytometry analysis of CD11b/c+ cells in circulation, * vs. other groups with different symbols (†, ‡, §), p<0.0001. (B) Flow 
cytometry analysis of Ly6G+ cells in circulation, * vs. other groups with different symbols (†, ‡, §), p<0.0001. (C) Flow cytometry analysis 
of VCAM-1+ cells in circulating platelets, * vs. other groups with different symbols (†, ‡, §), p<0.0001. (-) and (+) indicated without and 
with thrombin stimulation. (D) Flow cytometry analysis of CD3/CD4+ cells in circulation, * vs. other groups with different symbols (†, ‡, 
§), p<0.0001. (E) Flow cytometry analysis of CD3/CD8+ cells in circulation, * vs. other groups with different symbols (†, ‡, §), p<0.0001. 
(F) Flow cytometry analysis of Treg+ cells in circulation, * vs. other groups with different symbols (†, ‡, §), p<0.0001. All statistical 
analyses were performed by one-way ANOVA, followed by Bonferroni multiple comparison post hoc test (n=8 for each group). Symbols 
(*, †, ‡, §) indicate significance at 0.05 level. SC = sham control; ARDS = acute respiratory distress syndrome; SS = sepsis syndrome; 
HUCDMSC = human umbilical cord-derived mesenchymal stem cell; 1h indicated HUCDMSC administration at 1 hour after SS induction; 
24h indicated HUCDMSC administration at 24 hour after SS induction.
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Figure 10: Cellular expression of CD11+ and MIF+ cells in ascites by day 5 after ARDS-SS induction. (A to D) 
Immunofluorescent (IF) staining (400x) of CD11+ cells in ascites (green color). Nuclei were stained by DAPI (blue color). Red color in 
(C) and (D) indicated HUCDMSCs were found in kidney parenchyma. (E) Analytical result of CD11+ cells among the four groups, * vs. 
other groups with different symbols (†, ‡, §), p<0.0001. (F to I) IF image (400x) of macrophage migratory inhibitor (MIF)+ cells in ascites 
(green color). Nuclei were stained by DAPI (blue color). Red color in (H) and (I) indicated HUCDMSCs were found in kidney parenchyma. 
(J) Analytical of MIF+ cells among the four groups, * vs. other groups with different symbols (†, ‡, §), p<0.0001. Scale bars: 20 µm. All 
statistical analyses were performed by one-way ANOVA, followed by Bonferroni multiple comparison post hoc test (n=8 for each group). 
Symbols (*, †, ‡, §) indicate significance at 0.05 level. SC = sham control; ARDS = acute respiratory distress syndrome; SS = sepsis 
syndrome; HUCDMSC = human umbilical cord-derived mesenchymal stem cell; 1h indicated HUCDMSC administration at 1 hour after SS 
induction; 24h indicated HUCDMSC administration at 24 hour after SS induction.
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Figure 11: Cellular expression of IL-1ß+ and TLR+4 cells in ascites by day 5 after ARDS-SS induction. (A to D) 
Immunofluorescent (IF) image (400x) of interleukin (IL)-1ß+ cells in ascites (green color). Nuclei were stained by DAPI (blue color). Red 
color in (C) and (D) indicated HUCDMSCs were found in kidney parenchyma. (E) Analytical result of number of IL-1ß+ cells among the 
four groups, * vs. other groups with different symbols (†, ‡, §), p<0.0001. (F to I) IF (400x) of tall-like receptor (TLR)-4+ cells in ascites 
(green color). Nuclei were stained by DAPI (blue color). Red color in (H) and (I) indicated HUCDMSCs were found in kidney parenchyma. 
(J) Analytical result of TLR-4+ cells among the four groups, * vs. other groups with different symbols (†, ‡, §), p<0.0001. Scale bars: 20 
µm. All statistical analyses were performed by one-way ANOVA, followed by Bonferroni multiple comparison post hoc test (n=8 for each 
group). Symbols (*, †, ‡, §) indicate significance at 0.05 level. SC = sham control; ARDS = acute respiratory distress syndrome; SS = sepsis 
syndrome; HUCDMSC = human umbilical cord-derived mesenchymal stem cell; 1h indicated HUCDMSC administration at 1 hour after SS 
induction; 24h indicated HUCDMSC administration at 24 hour after SS induction.
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animals after receiving early HUCDMSC treatment, and 
further suppressed in ARDS-SS animals after receiving 
late HUCDMSC treatment.
A better prognostic outcome was coupled with an 
increased inflammatory and immune reaction in group 3 
(i.e., ARDS-SS + HUCDMSC1h), and vice versa in group 
4 (ARDS-SS + HUCDMSC24h). These unexpected findings 
could be explained by a few reasons. First, 95% of group 
3 animals were alive at the time of treatment, and about 
half had severe sepsis. The resulting organ damage (i.e., 
kidney parenchymal damage) can lead to relatively higher 
inflammatory and immune reactions. Second, nearly half 
of the group 4 animals were dead at the late treatment, 
suggesting the organ damage (i.e., the kidney parenchymal 
damage) should be relatively less severe in the animals that 
survived. This less severe damage would most likely not 
cause an overwhelming immune response relative to the other 
groups. Third, half-life and functionality of HUCDMSCs in 
animals is a possible factor resulting in differing inflammatory 
responses between group 3 and group 4.
Limitations
Although the short-term outcome in ARDS-SS rats 
was improved after the early HUCDMSC treatment, the long-
term outcome was not studied. Despite the albumin level in 
BAL fluid was found to be increased in ARDS-SS, we did 
not study whether ARDS, SS, or ARDS-SS was the most 
important contributor to this increase in lung permeability.
In conclusion, early administration of xenogeneic MSC 
suppressed the inflammatory/immune reaction, preserved the 
integrity of vital organs (i.e. lung and kidney), and reduced 
the mortality rate in rodents with induced ARDS-SS.
MATERIALS AND METHODS
Ethics
All animal experiments and procedures were 
approved by the Institute of Animal Care and Use 
Committee at Kaohsiung Chang Gung Memorial Hospital 
(Affidavit of Approval of Animal Use Protocol No. 
2011053001), and performed in accordance with the Guide 
for the Care and Use of Laboratory Animals [The Eighth 
Edition of the Guide for the Care and Use of Laboratory 
Animals (NRC 2011)].
Animals were housed in an Association for 
Assessment and Accreditation of Laboratory Animal Care 
International (AAALAC)-approved animal facility in our 
hospital with controlled temperature and light cycle (24oC 
and 12/12 light cycle).
Inducing ARDS and SS in rodents
The ARDS experimental model used in this study 
is described in our recent studies [17, 18], wherein pure 
oxygen (i.e., 100% O2) was continuously administered 
to the rat for 48 h. The SS induction procedure has been 
described in our previous report [34], which features a cecal 
ligation and puncture (CLP) 48 h after ARDS induction.
The tail systolic blood pressure (SBP) was measured 
with a CODA monitor (Kent Scientific Corporation, 
U.S.A.) at 28 h after CLP by a technician who was blinded 
to the treatment protocols.
Isolation and culture of HUCDMSCs
The HUCDMSCs were provided by BIONET Corp. 
(Taipei City, Taiwan). The protocol for HUCDMSC 
preparation was described as follows:
After obtaining informed consent, umbilical cords 
were collected and stored in DPBS (Gibco), and kept 
at 4ºC until processing. The cords were delivered to 
the laboratory in a bottle of sterile saline solution, and 
processed within 24 h after birth. The umbilical cords 
were first disinfected with 75% ethanol, and then washed 
with PBS to remove any contaminating blood.
After removing the blood vessels to avoid 
endothelial cell contamination, the cord tissue was cut 
into small pieces (0.5-1 mm3). The small pieces were 
placed directly into 10 cm culture dishes for growth 
in alpha-MEM (GIBCO, USA) supplemented with 
5% UltraGROTM (AventaCell, USA) and antibiotics 
(PSA, GIBCO). Cultures were maintained at 37ºC in a 
humidified atmosphere containing 5% CO2, replenished 
with fresh medium every 3-4 days. Near confluent 
cultures were rinsed with DPBS, harvested with 0.05% 
TrypLE (GIBCO, USA), and transferred to fresh 10 cm 
culture dishes at a plating density of 3-6 x 103 cells per 
cm2 for further growth. MSCs were then cryopreserved in 
culture medium containing 10% DMSO, using a control 
rate freezer (Icecube, Sylab, AT) and stored at -190ºC in a 
vapor phase liquid nitrogen tank.
Umbilical cord MSCs were stained with fluorescein 
isothiocyanate (FITC)- or phycoerythrin (PE)- conjugated 
antibodies against the following surface markers for flow 
cytometric analysis: CD13, CD14, CD29, CD31, CD34, 
CD44, CD45, CD73, CD90, HLA-DR, and CD105 (BD 
Pharmingen, San Diego, CA). Further, all MSC batches 
were tested for bacterial and fungal contamination (BacT 
Alert, Biomérieux, USA), mycoplasma (PCR, Biological 
industries USA), and endotoxin (LAL single vial test, 
Charles River Laboratories, USA), as well as anti-HTLV, 
anti-HIV, RPR, HBsAg, and anti-HCV.
Animal group treatment
Pathogen-free, adult male Sprague-Dawley (SD) 
rats weighing 325-350 g (Charles River Technology, 
BioLASCO Taiwan Co. Ltd., Taiwan) were randomized 
into four groups, with 16 animals per group. Group 1 
was the sham control (SC) group, which was subjected 
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to cecal exposure without ligation and puncture. Group 
2 (ARDS-SS + saline) had 3.0 cc saline administered 
intra-peritoneally at 1 h after CLP. Group 3 (ARDS-SS + 
HUCDMSC1h) and group 4 (ARDS-SS + HUCDMSC24h) 
animals were intravenously administered 1.2 x 106 
xenogeneic cells through the penis vein at 1 h and 24 h 
after CLP, respectively.
For both the bronchoalveolar lavage and cellular 
investigations, 12 surviving animals were required in each 
group (n = 6 in both subgroups). Including the number 
of dead animals, the number of rats utilized in groups 1 
to 4 were 20, 30, 20, and 25, respectively. Animals were 
euthanized by day 5 after ARDS-SS induction.
Bronchoalveolar lavage, and lung specimen 
preparation
The preparation of lung specimens for 
morphometric analyses is described in our previous 
studies [18, 36]. To elucidate the impact of HUCDMSC 
treatment on suppressing the inflammatory and immune 
reactions in lung parenchyma after ARDS-SS induction, 
bronchoalveolar lavage (BAL) was performed and the 
BAL fluid was collected for the study in six rats from each 
group.
Flow cytometric quantification of immune and 
inflammatory cells in circulation, ascites and 
BAL and abdominal ascites
The flow cytometry procedure for identification and 
quantification of circulating inflammatory and immune 
cells was based on our previous report [34]. Prior to 
sacrificing the animals, peripheral blood mononuclear 
cells (PBMCs) were obtained from the tail vein using a 
27# needle. PBMCs (1.0 x 106 cells) were triple-stained 
with FITC-anti-CD3 (BioLegend), PE-anti-CD8a (BD 
Bioscience, San Jose, CA, USA), and PE-Cy™5 anti-
CD4 (BD Bioscience, San Jose, CA, USA). To identify 
CD4+CD25+Foxp3+ regulatory T cells (Tregs), PBMCs 
were triple-stained with Alexa Fluor® 488-anti-CD25 
(BioLegend, San Diego, CA, USA), PE-anti-Foxp3 
(BioLegend, San Diego, CA, USA), and PE-Cy™5 anti-
CD4 (BD bioscience, San Jose, CA, USA) according to 
the manufacturer's protocol for the Foxp3 Fix/Perm buffer 
set. The numbers of CD3+CD4+ helper T cells, CD3+CD8+ 
cytotoxic T cells and CD4+CD25+Foxp3+ Tregs were 
analyzed using flow cytometry (FC500, Beckman Coulter, 
Brea, CA, USA).
Additionally, the numbers of inflammatory cells in 
circulation [i.e., CD11b/c, LyG6, vascular cell adhesion 
molecule (VCAM)-1], in ascites [macrophage migratory 
inhibitor factor (MIF), CD14, CD11b/c, LyG6, CD68/
CD80, CD68/CD163], and in ABL (CD11b/c, MIF, Ly6G) 
were assessed using the flow cytometric method.
Western blot analysis of kidney
The procedure and protocol for Western blot 
analysis were based on our recent reports [32, 35, 37]. 
Briefly, equal amounts (50 μg) of protein extracts were 
loaded and separated by SDS-PAGE using acrylamide 
gradients. After electrophoresis, the separated proteins 
were transferred electrophoretically to a polyvinylidene 
difluoride (PVDF) membrane (Amersham Biosciences, 
Amersham, UK). Nonspecific sites were blocked by 
incubation of the membrane in blocking buffer [5% 
nonfat dry milk in T-TBS (TBS containing 0.05% Tween 
20)] overnight. The membranes were incubated with 
the following primary antibodies for 1 hour at room 
temperature: cleaved poly (ADP-ribose) polymerase 
(PARP) (1:1000, Cell Signaling, Danvers, MA, USA), 
cleaved caspase 3 (1:1000, Cell Signaling, Danvers, 
MA, USA), matrix metalloproteinase (MMP)-9 (1:3000, 
Abcam, Cambridge, MA, USA), tumor necrosis factor 
(TNF)-α (1:1000, Cell Signaling, Danvers, MA, USA), 
nuclear factor (NF)-κB (1:600, Abcam, Cambridge, MA, 
USA), macrophage migration inhibitor factor (MIF)-1 
(1:2000, Abcam), tall-like receptor (TLR)-2 (1:1000, 
Novusbio), TLR-4 (1:500, Abcam), inducible nitric 
oxide synthase (iNOS) (1:200, Abcam, Cambridge, 
MA, USA), interleukin (IL)-1β (1:1000, Cell Signaling, 
Danvers, MA, USA), NOX-1 (1:2000, Sigma, St. Louis, 
Mo, USA), NOX-2 (1:500, Sigma, St. Louis, Mo, USA), 
IL-6 (1:500, Abcam), and actin (1: 10000, Chemicon, 
Billerica, MA, USA). Horseradish peroxidase-conjugated 
anti-rabbit immunoglobulin IgG (1:2000, Cell 
Signaling, Danvers, MA, USA) was used as a secondary 
antibody for one-hour incubation at room temperature. 
Membranes were washed eight times within one hour. 
Immunoreactive bands were visualized by enhanced 
chemiluminescence (ECL; Amersham Biosciences, 
Amersham, UK) and exposed to Biomax L film (Kodak, 
Rochester, NY, USA). For purposes of quantification, 
ECL signals were digitized using Labwork software 
(UVP, Waltham, MA, USA).
Immunohistochemical (IHC) and 
immunofluorescent (IF) staining
IF staining has been described in our previous reports 
[32, 35, 37]. For IHC and IF staining, rehydrated paraffin 
sections were first treated with 3% H2O2 for 30 minutes 
and incubated with Immuno-Block reagent (BioSB, Santa 
Barbara, CA, USA) for 30 minutes at room temperature. 
Sections were then incubated with primary antibodies 
specifically against CD68 (1:100, Abcam, Cambridge, MA, 
USA), CD14 (1:300, BioSS, Woburn, MA, USA), kidney 
injury molecule (KIM)-1 (1:500, R&D Systems), MIF-1 
(1:100, Abcam, Cambridge, MA, USA), and Wilm’s tumor 
suppressor gene (WT)-1 (1:1000, Abcam, Cambridge, 
MA, USA). Sections incubated with irrelevant antibodies 
Oncotarget45640www.impactjournals.com/oncotarget
served as controls. Three sections of kidney specimens were 
analyzed in each rat. For quantification, three randomly 
selected high power fields (HPFs; 400x for IHC and IF 
studies) were analyzed in each section. The mean number 
of positively-stained cells per HPF for each animal was 
determined across all nine HPFs.
An IHC-based scoring system was adopted for semi-
quantitative analyses of podocin and WT-1 as percentage 
of positive cells in a blind fashion [Score of positively-
stained cell for podocin and WT-1: 0 = no stain %; 1= 
<15%; 2 = 15~25%; 3 = 25~50%; 4 = 50~75%; 5= >75%-
100%/per HPF (400 x)].
Histopathological assessment of kidney injury at 
day 5 after ARDS-SS procedure
Histopathology scoring was assessed in a blinded 
fashion as we have previously described [32, 35, 37]. The 
scoring system reflecting the grading of tubular necrosis, 
loss of brush border, cast formation, and tubular dilatation 
in 10 randomly chosen, non-overlapping fields (200x) was 
as follows: 0 (none), 1 (≤10%), 2 (11–25%), 3 (26–45%), 
4 (46–75%), and 5 (≥76%).
Oxidative stress reaction in lung parenchyma
The procedure for assessing the protein expression 
of oxidative stress has been described in our previous 
reports [16, 18, 32, 35, 37], using the Oxyblot Oxidized 
Protein Detection Kit (Chemicon S7150, Billerica, MA, 
USA). For quantification, ECL signals were digitized 
using Labwork software (UVP, Waltham, MA, USA).
Statistical analysis
Quantitative data are expressed as mean ± SD. 
Statistical analysis was performed by ANOVA, followed 
by Bonferroni multiple-comparison post hoc test. 
Statistical analysis was also performed using SPSS (SPSS 
for Windows, version 13; SPSS, IL, U.S.A.). The threshold 
for statistical significance was considered P < 0.05.
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